Last reviewed · How we verify

NCT04774198

Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy

Completed Last updated 6 April 2025
What this trial tests

trial testing blood sample in Pancreas Cancer in 48 participants. Completed in 7 January 2024.

Timeline
1 February 2021
Primary endpoint
7 December 2023
7 January 2024

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date1 February 2021
Primary completion7 December 2023
Estimated completion7 January 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Perioperative immunologic signatures can predict the risk of postoperative complications. The results will be puplished as two smanuscripts. The manuscript will focus on preoperative immunologisk data,the second manuscript will include both pre- and postoperative data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of blood sample

Trials testing the same drug.

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04774198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing